All Industries

Top Therapeutics Companies

203 Therapeutics companies, sorted by total funding raised.

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Life Sciences
Series D·$1.4B·Jun 2020
Abogen Biosciences

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.

Suzhou, China201–500Biotech, mRNA Therapeutics
Extension Round·$1.1B·Nov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate Round·$1.0B·Apr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series C·$955.0M·Sep 2024
Candid Therapeutics

Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...

San Diego, United States11–50Biotech, Therapeutics
Venture Unknown·$875.0M·Mar 2026
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech, Genomics
Corporate Round·$730.0M·Dec 2025
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Life Sciences
Venture Unknown·$722.0M·Jul 2025
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series B·$650.0M·Oct 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private Equity·$647.0M·Feb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series B·$612.0M·Oct 2022
Edgewise TherapeuticsIPO

Clinical-stage biopharmaceutical company developing oral therapies for serious skeletal and cardi...

Boulder, United States51–200Biotech, Therapeutics
Growth Equity·$585.0M·Apr 2025
CelcuityIPO

Minneapolis-based clinical stage biotechnology company focused on the development of molecularly ...

Minneapolis, United States51–200Biotech, Diagnostics
Convertible·$550.1M·Aug 2025
Beam TherapeuticsIPO

Biotechnology company developing precision genetic medicines through proprietary base editing tec...

Cambridge, United States201–500Biotech, Gene Editing
Growth Equity·$528.0M·Feb 2026
Relay TherapeuticsIPO

Clinical-stage precision medicines company using protein-motion-driven drug discovery to design s...

Cambridge, United States51–200Biotech, Drug Discovery
Series C·$520.0M·Dec 2018
RAPT TherapeuticsIPO

Clinical-stage biopharmaceutical developing immune-targeting therapeutics for inflammatory and im...

San Francisco, United States51–200Biotech, Healthcare
Private Equity·$497.0M·Oct 2025
GenentechIPO

Biotechnology company that discovers and develops medicines for serious, life-threatening disease...

San Francisco, United States10001+Biotech, Drug Discovery
Corporate Round·$492.3M·Feb 1990
ImmunomedicsClosed

Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...

Morris Plains, United States201–500biotechnology, oncology
Private Equity·$459.0M·May 2020
Crinetics Pharmaceuticals, Inc.

R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.

San Diego, United States11–50Biotech, Healthcare
Venture Unknown·$453.5M·Jan 2026
Phathom PharmaceuticalsIPO

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing ...

Florham Park, United States201–500Biotech, GI Health
Venture Unknown·$450.3M·May 2023
GalectoIPO

Clinical-stage biotech developing small-molecule therapeutics targeting galectin and other mechan...

Copenhagen, Denmark11–50Biotech, Drug Development
Series C·$446.9M·Nov 2025
X4 PharmaceuticalsIPO

Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a ran...

Boston, United States51–200Biotech, Drug Discovery
Series C·$446.8M·Oct 2025
Verve TherapeuticsAcquired

Develops one-time in vivo gene-editing medicines to prevent and treat atherosclerotic cardiovascu...

Boston, United States201–500Biotech, Drug Discovery
Series C·$428.5M·Oct 2024
Areteia TherapeuticsClosed

Clinical-stage biotechnology developing an oral eosinophil-maturation inhibitor (dexpramipexole) ...

Chapel Hill, United States11–50Biotech, Life Sciences
Series A·$425.0M·Feb 2024
Verdiva Bio

Verdiva Bio is a clinical-stage biopharmaceutical company focused on developing innovative therap...

London, United Kingdom11–50Life Sciences, Biotech
Series A·$411.0M·Jan 2025
Sonoma Biotherapeutics

Develops engineered regulatory T cell therapies to restore immune balance and treat autoimmune an...

Seattle, United States51–200Biotech, Life Sciences
Corporate Round·$410.0M·Sep 2024